"Innovator and explorer in the field of pediatric medicine in China"Bemei’s 2021 Annual Meeting was successfully concluded!It’s the season of spring, at 2:00 pm on March 5, 2021, Bemei’s 2021 Annual Meeting was held in the conference center of Kexing Science Park.Focusing on the theme of "Innovator and explorer in China's pediatric drug field", Ms. Wu G...

Shenzhen Beimei Pharma completedA roundfinancingOn 26th January 2021,Shenzhen Beimei Pharma Co., Ltd.(hereinafter referred to as "Beimei Pharma") officially announced the completion of A roundfinancing of tens of millions of RMB, invested by Sunhope Investment Group(hereinafter referred to as "Sunhope"). This round of financing will be mainly used for R&a...

Beimei Pharma and Deva Holding A.Ş. reached an exclusive license and supply agreement in China for one product that have been approved for marketing in European On December 2, 2020, Shenzhen Beimei Pharma Co., Ltd. (hereinafter referred to as "Beimei Pharma") and Deva Holding A.Ş. of Turkey (hereinafter referred to as "De...

Beimei Pharma and Ciplareached an exclusive license and supply agreementin China for two products that have been approved for marketing in the United StatesOn October 9, 2020, Shenzhen Beimei PharmaCo., Ltd. (hereinafter referred to as "Beimei Pharma") and Cipla Ltd (hereinafter referred to as "Cipla") signed an exclusive and supplyagreementin China for two p...

Beimei Pharma and EMP Pharma reached an exclusive licenseand supplyagreement for an innovativeoral solution in ChinaOn August 25, 2020, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as “Beimei Pharma”) and EMP Pharmaceuticals BV of the Netherlands (hereinafter referred to as “EMP Pharma”) signed an exclusive licenseand supplyagreement on an innova...

Announcement on Application Acceptance of Lacosamide Oral Solution Generic Name: Lacosamide Oral Solution Dosage form: Oral solution Registration Category: 5.2 Category Our company and HETERO LABS LIMITED, Indiahasreached a cooperation on Lacosamide Oral Solution in 2019. We are exclusively responsible for the registration and commercialization of this produc...

Today, the CDE released Technical Guidelines for Real-World Evidence in Support of Pediatric Medicines Development and Review (Draft for Comment), which clearly states that using real-world evidence is a strategy for Pediatric Medicines development. As early as May 29 last year, the CDE published Real-World Evidence to Support Basic Considerations for Drug Developm...

On April 23rd, Shenzhen Beimei Pharmaceutical Co., Ltd. announced the opening of the first laboratory of the Beimei Pediatric Medicine Development Center.

Our company and HETERO LABS LIMITED of India reached cooperation on Oseltamivir Phosphate for Oral Suspension at the beginning of this year.